Your account is not claimed yet. You can sign up with ORCID to claim your account.

Elisa Camela (E Camela)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 46

Top Venues

Expert opinion on drug safety

Dermatologic therapy

Medicina (Kaunas, Lithuania)

Psoriasis (Auckland, N.Z.)

This page only lists publications with an associated author ORCID identifier.

Publications

Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Sabatino Pallotta, Matteo Megna
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert opinion on investigational drugs (2023)
Elisa Camela, Paula Ilut Anca, Konstantinos Lallas, Chryssoula Papageorgiou, Sofia-Magdalini Manoli, Theodosia Gkentsidi, Polychronia Eftychidou, Konstantinos Liopyris, Dimitrios Sgouros, Zoe Apalla, Aimillios Lallas
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Angelo Ruggiero, Matteo Megna
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert opinion on drug safety (2023)
Luca Potestio, Teresa Battista, Sara Cacciapuoti, Ruggiero Angelo, Fabrizio Martora, Luigi Fornaro, Elisa Camela, Matteo Megna
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge. Biomedicines 11 (8) (2023)
Elisa Camela, Paula Ilut Anca, Konstantinos Lallas, Chryssoula Papageorgiou, Sofia-Magdalini Manoli, Theodosia Gkentsidi, Polychronia Eftychidou, Konstantinos Liopyris, Dimitrios Sgouros, Zoe Apalla, Aimillios Lallas
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Elisa Camela, Paula Ilut Anca, Konstantinos Lallas, Chryssoula Papageorgiou, Sofia-Magdalini Manoli, Theodosia Gkentsidi, Polychronia Eftychidou, Konstantinos Liopyris, Dimitrios Sgouros, Zoe Apalla, Aimillios Lallas
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Ruggiero Angelo, Fabrizio Martora, Teresa Battista, Matteo Megna
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical, cosmetic and investigational dermatology 16 (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Ruggiero Angelo, Teresa Battista, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? Clinical, cosmetic and investigational dermatology 16 (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety 22 (1) (2023)
Elisa Camela, Paula Ilut Anca, Konstantinos Lallas, Chryssoula Papageorgiou, Sofia-Magdalini Manoli, Theodosia Gkentsidi, Polychronia Eftychidou, Konstantinos Liopyris, Dimitrios Sgouros, Zoe Apalla, Aimillios Lallas
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety (2022)
Matteo Megna, Elisa Camela, Alessia Villani, Andrea Tajani, Gabriella Fabbrocini, Luca Potestio
Teledermatology: A useful tool also after COVID-19 era? Journal of cosmetic dermatology 21 (6) (2022)
Matteo Megna, Elisa Camela, Ruggiero Angelo, Gabriella Fabbrocini, Luca Potestio
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al. International journal of dermatology 61 (10) (2022)
Elisa Camela, Massimiliano Scalvenzi, Matteo Megna, Luca Potestio, Gianluca Guerrasio, Luigi Fornaro, Gabriella Fabbrocini, Claudia Costa
Reply to "A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination" by Manaa et al. Dermatologic therapy (2022)
Elisa Camela, Alessia Villani, Massimiliano Scalvenzi, Claudia Costa
Giant basal cell carcinoma of the vulva successfully treated with Sonidegib. Dermatologic therapy 35 (9) (2022)
Ruggiero Angelo, Fabrizio Martora, Vincenzo Picone, Luca Potestio, Elisa Camela, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clinical and experimental dermatology 47 (12) (2022)
Claudio Marasca, Maria Carmela Annunziata, Elisa Camela, Adriana Di Guida, Luigi Fornaro, Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Luca Potestio, Gabriella Fabbrocini
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. Journal of clinical medicine 11 (6) (2022)
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Ruggiero Angelo
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. Dermatologic therapy 35 (9) (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety 21 (12) (2022)
Matteo Megna, Laura Marano, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Massimiliano Scalvenzi, Gianluca Guerrasio
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab. Dermatologic therapy 35 (10) (2022)
Elisa Camela, Luca Potestio, Ruggiero Angelo, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Matteo Megna
Towards Personalized Medicine in Psoriasis: Current Progress. Psoriasis (Auckland, N.Z.) 12 (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety (2022)
Ruggiero Angelo, Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Matteo Megna
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckland, N.Z.) 12 (2022)
Matteo Megna, Alessia Villani, Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza
Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation. Dermatologic therapy 35 (9) (2022)
Matteo Megna, Luca Potestio, Ruggiero Angelo, Elisa Camela, Gabriella Fabbrocini
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. Dermatologic therapy 35 (7) (2022)
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Paradoxical reactions to biologicals for psoriasis. Expert opinion on biological therapy (2022)
Matteo Megna, Luigi Fornaro, Luca Potestio, Maria Antonietta Luciano, Mariateresa Nocerino, Mario Delfino, Maria Guarino, Gabriella Fabbrocini, Elisa Camela
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study. Psoriasis (Auckland, N.Z.) 12 (2022)
Ruggiero Angelo, Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Matteo Megna
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert opinion on drug safety 21 (12) (2022)
Matteo Megna, Luca Potestio, Teresa Battista, Elisa Camela, Lucia Genco, Matteo Noto, Gabriella Fabbrocini, Fabrizio Martora
Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clinical and experimental dermatology 47 (12) (2022)
Sonia Sofia Ocampo-Garza, Alessia Villani, Eleonora Cinelli, Elisa Camela, Gabriella Fabbrocini, Matteo Megna
Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation. Dermatologic therapy 35 (4) (2022)
Ruggiero Angelo, Luca Potestio, Sara Cacciapuoti, Lucia Gallo, Teresa Battista, Elisa Camela, Gabriella Fabbrocini, Matteo Megna
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study. Dermatologic therapy (2022)
Matteo Megna, Luigi Fornaro, Mario De Lucia, Orsola Rescigno, Elisa Camela, Gabriella Fabbrocini
A case of pediatric psoriasis successfully and rapidly treated with ixekizumab. Dermatologic therapy 34 (6) (2021)
Matteo Megna, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Eleonora Cinelli, Ruggiero Angelo, Elisa Camela
A case of erythrodermic psoriasis successfully treated with apremilast. Dermatologic therapy (2021)
Elisa Camela, G Guerrasio, C Patruno, M Scalvenzi, N Di Caprio, G Fabbrocini, Maddalena Napolitano
Reply to 'New-onset cutaneous lichen planus triggered by COVID-19 vaccination' by Merhy et al. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (4) (2021)
Matteo Megna, Elisa Camela, Sonia S Ocampo Garza, Vincenzo Marino, Luca Costanzo, Massimiliano Scalvenzi, Gabriella Fabbrocini, Lucia Gallo
Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient. Contact dermatitis 85 (4) (2021)
Ruggiero Angelo, G Fabbrocini, Eleonora Cinelli, S S Ocampo Garza, Elisa Camela, Matteo Megna
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clinical and experimental dermatology (2021)
Chiara Miano, Matteo Megna, Paola Di Caterino, Emilio Berti, Gabriella Fabbrocini, Elisa Camela
An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy: A new subtype? Dermatologic therapy 34 (2) (2021)
Luca Potestio, Elisa Camela, Gabriella Fabbrocini, Matteo Megna
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5". Journal of cosmetic dermatology 20 (12) (2021)
Elisa Camela, Sonia Sofia Ocampo-Garza, Eleonora Cinelli, Alessia Villani, Gabriella Fabbrocini, Matteo Megna
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatologic therapy 34 (2) (2021)

Elisa Camela.css-eqlu8i{font-size:small;padding-left:4px;} (E Camela)

Publication Activity (10 Years)

Top Topics

Top Venues

Elisa Camela (E Camela)